Magnesium supplements offer
clinically significant reductions in
blood pressure, according to a study
in this month's European
Journal of Clinical Nutrition.
Data from 22 trials with magnesium
supplements revealed that it reduced
systolic and diastolic blood
pressure by 4 and 3mmHg,
respectively on average.
Systolic function relates to the
contraction of the heart, whereas
diastolic relates to the filling of
the heart with blood. Magnesium
supplementation doses ranged from
120 to 973mg with a duration from
three to 24 weeks. The overall data
indicated that magnesium
supplementation achieved optimum
results when doses were
approximately 370 milligrams per
wonderful news on magnesium. Great
to see that the average dose we
usually recommend, 400 mg., was the
Here We Go Again. Another
Obesity Drug to Be Approved.
A panel of medical experts
voted to endorse the controversial
obesity drug Qnexa, clearing the way
for the Food and Drug Administration
to approve a new prescription
obesity medication for the first
time since 1999. The FDA will issue
a final ruling later this year, but
the agency typically follows the
recommendations of its advisory
In 2010, the same
advisory committee decided that the
drug's risks of heart problems and
birth defects outweighed its
combination of the anticonvulsant
drug topiramate and the appetite
suppressant phentermine, led to an
average loss of 10% of total body
weight in the first year of use.
trials also found that that the drug
caused a slight increase in heart
rate, which can boost the odds of a
heart attack or stroke. In addition,
researchers detected an increased
risk of birth defects - typically
cleft lip - in women who became
pregnant while taking the
drug. According to the clinical
trial data and previous studies, the
risk of having a baby with a cleft
lip is two to five times greater in
women who took Qnexa.
panel's vote sure made the
manufacturer happy. Their stock
price soared after the announcement.
Will it make patients happy?
Revisionist history with regard to
obesity drugs says no.
our opinion, we do not recommend
touching this med until at least 3
or 4 years of post-market research
on its side effects has been
performed. Besides, does the
economic cost and potential for
adverse effects in exchange for a
ten percent reduction of body weight
seem like a good trade-off?
Take Sleeping Pills? Your Mortality
Risk Rises Four-Fold.
According to a study published
in this week's BMJ
Open, sleeping pills were
linked to a more than fourfold risk
of premature death. They
were also associated at higher doses
with a 35 percent increased risk of
cancer as compared with non-users.
10,500 subjects who took between 18
and 132 doses of sleeping pills per
year were 4.6 times likelier to die
than 23,600 subjects who did not
take them. Even those who took less
than 18 annual doses were more than
3.5 times likelier to die. "Rough
order-of-magnitude estimates suggest
that in 2010, sleeping pills may
have been associated with 320,000 to
507,000 excess deaths in the USA
alone," says the study.
data, but will our government
agencies investigate this? If you
are considering weaning off sleeping
pills, contact your physician and
pharmacist for a smart protocol.
Non-pharmacological options, such as
magnesium, as well as other
suggestions found in ourSleep
Well Action Plan,
may be of assistance.